Clonal evolution: a landmark of MPN evolution

Myeloproliferative Neoplasms comprise a heterogeneous group of diseases characterized over the past two decades by the acquisition of somatic mutations in hematopoietic stem cells, leading to a pre-leukemic state. The natural history of the disease is marked by the sequential acquisition of genetic events that play an essential role in the phenotype, evolution and response to treatment of the disease. Indeed, disease progression is as heterogeneous as the variety of genetic abnormalities found in individual patients, some of whom lead to disease evolution with a pejorative prognosis, while others persist in a benign manner. In order to better explore these questions, it is important to better understand: (1) the genetic structure of the tumor through dynamic reconstruction of clonal architecture (2) the factors favoring the development of certain clones and their expansion, some of which are governed by Darwinian laws. These parameters could help explain the heterogeneity between MPN patients with similar genetic profiles, and prevent the emergence of clones identified as aggressive by the use of innovative therapeutic strategies targeting new pathways to prevent early transformations in poor prognosis MPN subtypes.

Authors

Institutions

Publication Details

Journal
Frontiers in Hematology
Published
2024-10-07
DOI
https://doi.org/10.3389/frhem.2024.1473920
Primary Topic
Myeloproliferative Neoplasms: Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Clonal evolution: a landmark of MPN evolution

Jean‐Jacques Kiladjian, Nabih Maslah, Stéphane Giraudier, Bruno Cassinat
Frontiers in Hematology
Myeloproliferative Neoplasms: Diagnosis and Treatment
article

Clonal evolution: a landmark of MPN evolution

Jean‐Jacques Kiladjian, Nabih Maslah, Stéphane Giraudier, Bruno Cassinat
article en

Abstract

Myeloproliferative Neoplasms comprise a heterogeneous group of diseases characterized over the past two decades by the acquisition of somatic mutations in hematopoietic stem cells, leading to a pre-leukemic state. The natural history of the disease is marked by the sequential acquisition of genetic events that play an essential role in the phenotype, evolution and response to treatment of the disease. Indeed, disease progression is as heterogeneous as the variety of genetic abnormalities found in individual patients, some of whom lead to disease evolution with a pejorative prognosis, while others persist in a benign manner. In order to better explore these questions, it is important to better understand: (1) the genetic structure of the tumor through dynamic reconstruction of clonal architecture (2) the factors favoring the development of certain clones and their expansion, some of which are governed by Darwinian laws. These parameters could help explain the heterogeneity between MPN patients with similar genetic profiles, and prevent the emergence of clones identified as aggressive by the use of innovative therapeutic strategies targeting new pathways to prevent early transformations in poor prognosis MPN subtypes.

Frontiers in HematologyVol. 3
Inserm (FR), Université Paris Cité (FR), Assistance Publique – Hôpitaux de Paris (FR), Hôpital Saint-Louis (FR)
Ligue Contre le Cancer, Institut National Du Cancer, Institute of Cancer Research
No poverty
Openalex Percentile: Top 71%
Myeloproliferative Neoplasms: Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Clonal evolution: a landmark of MPN evolution — Jean‐Jacques Kiladjian, Nabih Maslah, et al. · Frontiers in Hematology (2024) | TGRS Research Map | TGRS